JPRN-UMIN000003506已完成1 期
Fhase I clinical study of WT1 petide-based immnotherapy using WT1 helper peptide for recurrent malignant glioma - Fhase I clinical study of WT1 petide-based immnotherapy using WT1 helper peptide for recurrent malignant glioma
Department of Cancer immunotherapy, Osaka University Graduate School of Medicine0 个研究点目标入组 18 人开始时间: 2010年4月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. There is deep-seated active infection. 2,3. There are severe complications including malignant hypertention, cardiac failure, liver cirrhosis, severe DM, severe lung fiblosis, active interstitial pneumonitis.Patients who have complications that are considered inappropriate for the trial. 4. Dependent on total parenteral nutrition(TPN) 5. There are other malignancies. 6. There are hematopoietic stem cell disorders such as myelodisplastic syndorome(MDS) and myeloproliferative disorders (MPD). 7. Post allogeneic hematopoietic stem cell transplantation 8. Pregnant or lactating woman 9. There is severe psychiatric disorder. 10. Responsible doctors judged the patient inappropriate for the trial
研究者
相似试验
已完成
不适用
Phase I/II clinical study of WT1 peptide-based immunotherapy combined with Imatinib for chronic myelogeneous leukemiaJPRN-UMIN000003508Department of Cancer immunotherapy, Osaka University Graduate School of Medicine30
已完成
不适用
Phase I clinical trial of immunotherapy with WT1 peptide vaccine for hematological malignancies after stem cell transplantatioAcute myeloid or lymphoid leukemia malignant lymphoma multiple myelomaJPRN-UMIN000004753Osaka University6
已完成
1 期
A phase I/II study of a WT1-W10 immunotherapy against high-risk MDS and MDS overt AML.High-risk MDS and MDS overt AMJPRN-UMIN000026023Department of Hematology and respiratory Medicine, School of Medicine, Kochi University60
已完成
不适用
Phase II clinical trial of immunotherapy with WT1 peptide vaccination for pediatric hematological malignancies after allogeneic stem cell transplantation.Acute lymphoid or myeloid leukemia, acute unclassified leukemia, malignant lymphomaJPRN-UMIN000005319Osaka University22
招募中
1 期
Phase 1 study of WT1 peptide vaccine therapy for high risk leukemia patients after hematopoietic stem cell transplantatioAcute myeloid leukemia, Acute lymphoblastic leukemia, Chronic myeloid leukemia blastic phase, Myelodysplastic syndrome with high risk of relapse and/or excess blastsJPRN-UMIN000002089ational Cancer Research Center Hospital18